Citations

Clear

9383 citation(s) found for "Thomas, PS".

Clinical Pharmacology: A Paradigm for Individualized Medicine
Waldman, Scott A. , Kraft, Walter K. , Nelson, Timothy J. , Terzic, André , Nelson, Timothy J , Waldman, Scott A

Mayo Clinic

Biomarkers in Medicine | December 15, 2009 | Volume: 3 | Issue: 6 | Pages: 679-684

10.2217/bmm.09.76 | PMID 20477706 Get It

Statin Use and Prognosis in Patients With Diffuse Large B-Cell Lymphoma and Follicular Lymphoma in the Rituximab Era
Nowakowski, Grzegorz S. , Maurer, Matthew J. , Ansell, Stephen M. , Macon, William R. , Ristow, Kay M., Allmer, Cristine, Cerhan, James R. , Habermann, Thomas M. , Slager, Susan L. , Witzig, Thomas E. , Maurer, Matthew , Cerhan, James R

Mayo Clinic

Journal of Clinical Oncology | December 14, 2009 | Volume: 28 | Issue: 3 | Pages: 412-417

10.1200/jco.2009.23.4245 | PMID 20008638 Get It

Purpose Statins have antilymphoma properties but have also been shown to inhibit the binding of rituximab to the CD20 antigen, resulting in reduced antitumor activity of rituximab in vitro. The clinical impact of statin use on the outcome of lymphoma patients treated with a rituximab-containing regimen is unknown. Patients and Methods Consecutive patients with newly diagnosed, diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma (FL) were enrolled onto a registry and observed prospectively. The impact of statin use on patients' outcomes was analyzed. Results Two hundred twenty-eight patients with DLBCL and 293 patients with FL were enrolled from September 2002 through June 2007; 21% of patients with DLBCL and 19% of patients with FL were on statins at diagnosis, and 20% and 17% remained on statins during lymphoma treatment, respectively. All patients with DLBCL and 39% of patients with FL received initial therapy containing rituximab. The median follow-up time was 47 months (range, 13 to 80 months). Statin use had no impact on the overall response rate (P = .67), overall survival (P = .76), or event-free survival (EFS) in patients with DLBCL (hazard ratio [HR] = 0.85; 95% CI, 0.43 to 1.68). Statin use at diagnosis was associated with improved EFS in patients with FL (HR = 0.45; 95% CI, 0.26 to 0.77), including subgroups treated with rituximab or a rituximab-containing regimen (HR = 0.38; 95% CI, 0.14 to 1.07) and patients who were observed only (HR = 0.38; 95% CI, 0.17 to 0.84). Conclusion The concurrent use of statins during the treatment of patients with DLBCL and FL in the rituximab era did not adversely affect outcome. The apparent benefit of statin therapy on FL outcome requires further studies.
Lenalidomide plus dexamethasone versus thalidomide plus dexamethasone in newly diagnosed multiple myeloma: a comparative analysis of 411 patients
Gay, Francesca , Hayman, Suzanne R. , Lacy, Martha Q. , Kumar, Shaji , Dispenzieri, Angela , Bergsagel, P. Leif , Dingli, David , Reeder, Craig B. , Lust, John A., Russell, Stephen J. , Zeldenrust, Steven R., Fonseca, Rafaël , Kyle, Robert A. , Greipp, Philip R., Stewart, A. Keith, Rajkumar, S. Vincent , Buadi, Francis K. , Gertz, Morie A. , Mıkhael, Joseph , Roy, Vivek , Witzig, Thomas E. , Bergsagel, P. Leif , Rajkumar, S Vincent , Dispenzieri, Angela , Russell, Stephen J , Dingli, David , Gay, Francesca , Fonseca, Rafael

Mayo Clinic

Blood | December 12, 2009 | Volume: 115 | Issue: 7 | Pages: 1343-1350

10.1182/blood-2009-08-239046 | PMID 20008302 Get It

AbstractThe objective of this case-control study was to compare the efficacy and toxicity of lenalidomide plus dexamethasone (len/dex) versus thalidomide plus dexamethasone (thal/dex) as initial therapy for newly diagnosed myeloma. We retrospectively studied 411 newly diagnosed patients treated with len/dex (228) or thal/dex (183) at the Mayo Clinic. The differences were similar in a matched-pair analysis that adjusted for age, sex, transplantation status, and dexamethasone dose. The proportions of patients achieving at least a partial response to len/dex and thal/dex were 80.3% versus 61.2%, respectively (P < .001); very good partial response rates were 34.2% and 12.0%, respectively (P < .001). Patients receiving len/dex had longer time to progression (median, 27.4 vs 17.2 months; P = .019), progression-free survival (median, 26.7 vs 17.1 months; P = .036), and overall survival (median not reached vs 57.2 months; P = .018). A similar proportion of patients in the 2 groups experienced at least one grade 3 or 4 adverse event (57.5% vs 54.6%, P = .568). Main grade 3 or 4 toxicities of len/dex were hematologic, mainly neutropenia (14.6% vs 0.6%, P < .001); the most common toxicities in thal/dex were venous thromboembolism (15.3% vs 9.2%, P = .058) and peripheral neuropathy (10.4% vs 0.9%, P < .001). Len/dex appears well-tolerated and more effective than thal/dex. Randomized trials are needed to confirm these results.
Daily Oral Everolimus Activity in Patients With Metastatic Pancreatic Neuroendocrine Tumors After Failure of Cytotoxic Chemotherapy: A Phase II Trial
Yao, James C. , Baudin, Éric , Kvols, Larry K., Rougier, Philippe, Ruszniewski, Philippe, Hoosen, Sakina, Peter, J., Haas, T , Lebwohl, David , Kulke, Matthew H. , Hobday, Timothy J. , O’Dorisio, Thomas M. , Shah, Manisha H. , Cadiot, Guillaume , Luppi, Gabriele , Posey, James , Wiedenmann, Bertram , Lombard‐Bohas, Catherine , Cutsem, Eric Van

Mayo Clinic

Journal of Clinical Oncology | November 23, 2009 | Volume: 28 | Issue: 1 | Pages: 69-76

10.1200/jco.2009.24.2669 | PMID 19933912 Get It

Purpose No established treatment exists for pancreatic neuroendocrine tumor (NET) progression after failure of chemotherapy. Everolimus (RAD001), an oral inhibitor of mammalian target of rapamycin, in combination with octreotide has demonstrated encouraging antitumor activity in patients with NETs. Patients and Methods This open-label, phase II study assessed the clinical activity of everolimus in patients with metastatic pancreatic NETs who experienced progression on or after chemotherapy. Patients were stratified by prior octreotide therapy (stratum 1: everolimus 10 mg/d, n = 115; stratum 2: everolimus 10 mg/d plus octreotide long-acting release [LAR], n = 45). Tumor assessments (using Response Evaluation Criteria in Solid Tumors) were performed every 3 months. Chromogranin A (CgA) and neuron-specific enolase (NSE) were assessed monthly if elevated at baseline. Trough concentrations of everolimus and octreotide were assessed. Results By central radiology review, in stratum 1, there were 11 partial responses (9.6%), 78 patients (67.8%) with stable disease (SD), and 16 patients (13.9%) with progressive disease; median progression-free survival (PFS) was 9.7 months. In stratum 2, there were two partial responses (4.4%), 36 patients (80%) with SD, and no patients with progressive disease; median PFS was 16.7 months. Patients with an early CgA or NSE response had a longer PFS compared with patients without an early response. Coadministration of octreotide LAR and everolimus did not impact exposure to either drug. Most adverse events were mild to moderate and were consistent with those previously seen with everolimus. Conclusion Daily everolimus, with or without concomitant octreotide LAR, demonstrates antitumor activity as measured by objective response rate and PFS and is well tolerated in patients with advanced pancreatic NETs after failure of prior systemic chemotherapy.
Safety Studies on Intrahepatic or Intratumoral Injection of Oncolytic Vesicular Stomatitis Virus Expressing Interferon-β in Rodents and Nonhuman Primates
Jenks, Nathan, Myers, Rae, Greiner, Suzanne , Thompson, Jill , Mader, Emily K., Greenslade, Andrew, Griesmann, Guy E., Federspiel, Mark J. , Rakela, Jorge , Vile, Richard G. , Barber, Glen N. , Meier, Thomas R., Blanco, Michael C., Carlson, Stephanie K., Russell, Stephen J. , Peng, Kah-Whye , Jenks, Nathan J., Borad, Mitesh J. , Russell, Stephen J

Mayo Clinic

Human Gene Therapy | November 13, 2009 | Volume: 21 | Issue: 4 | Pages: 451-462

10.1089/hum.2009.111 | PMID 19911974 Get It

Free Fatty Acid-Induced Hepatic Insulin Resistance is Attenuated Following Lifestyle Intervention in Obese Individuals with Impaired Glucose Tolerance
Haus, Jacob M. , Solomon, Thomas P. J. , Marchetti, Christine M., Edmison, John M., González, Frank , Kirwan, John P.

Mayo Clinic

The Journal of Clinical Endocrinology & Metabolism | November 11, 2009 | Volume: 95 | Issue: 1 | Pages: 323-327

10.1210/jc.2009-1101 | PMID 19906790 Get It

Defining Value in Spine Care
Rihn, Jeffrey A. , Berven, Sigurd, Phillips, Frank M. , Currier, Bradford L. , Glassman, Steven D. , Nash, David B. , Mick, Charles, Crockard, Alan, Albert, Todd J., Allen, Todd M.

Mayo Clinic

American Journal of Medical Quality | November 4, 2009 | Volume: 24 | Issue: 6_suppl | Pages: 4S-14S

10.1177/1062860609349214 | PMID 19890180 Get It

Recognition of Fungal Protease Activities Induces Cellular Activation and Eosinophil-Derived Neurotoxin Release in Human Eosinophils
Matsuwaki, Yoshinori , Wada, Kota, White, Thomas A. , Benson, Linda M., Charlesworth, M. Cristine , Checkel, James L., Inoue, Yoshinari, Hotta, Kyôko, Ponikau, Jens U., Lawrence, Christopher B. , Kita, Hirohito , Charlesworth, M. Cristine , Hotta, Kyoko, Kita, H

Mayo Clinic

The Journal of Immunology | October 29, 2009 | Volume: 183 | Issue: 10 | Pages: 6708-6716

10.4049/jimmunol.0901220 | PMID 19864598 Get It

Abstract Eosinophils are multifunctional leukocytes implicated in the pathogenesis of asthma and in immunity to certain organisms. Associations between exposure to an environmental fungus, such as Alternaria, and asthma have been recognized clinically. Protease-activated receptors (PARs) are G protein-coupled receptors that are cleaved and activated by serine proteases, but their roles in innate immunity remain unknown. We previously found that human eosinophils respond vigorously to Alternaria organisms and to the secretory product(s) of Alternaria with eosinophils releasing their proinflammatory mediators. In this study, we investigated the roles of protease(s) produced by Alternaria and of PARs expressed on eosinophils in their immune responses against fungal organisms. We found that Alternaria alternata produces aspartate protease(s) and that human peripheral blood eosinophils degranulate in response to the cell-free extract of A. alternata. Eosinophils showed an increased intracellular calcium concentration in response to Alternaria that was desensitized by peptide and protease ligands for PAR-2 and inhibited by a PAR-2 antagonistic peptide. Alternaria-derived aspartate protease(s) cleaved PAR-2 to expose neo-ligands; these neo-ligands activated eosinophil degranulation in the absence of proteases. Finally, treatment of Alternaria extract with aspartate protease inhibitors, which are conventionally used for HIV-1 and other microbes, attenuated the eosinophils’ responses to Alternaria. Thus, fungal aspartate protease and eosinophil PAR-2 appear critical for the eosinophils’ innate immune response to certain fungi, suggesting a novel mechanism for pathologic inflammation in asthma and for host-pathogen interaction.
Nicotine response genetics in the zebrafish
Petzold, Andrew M. , Balciunas, Darius , Sivasubbu, Sridhar , Clark, Karl J. , Bedell, Victoria M. , Westcot, Stephanie, Myers, Shelly R., Moulder, Gary, Thomas, Mark J. , Ekker, Stephen C. , Ekker, Stephen C , Clark, Karl J , Balciunas, Darius

Mayo Clinic

Proceedings of the National Academy of Sciences | October 26, 2009 | Volume: 106 | Issue: 44 | Pages: 18662-18667

10.1073/pnas.0908247106 | PMID 19858493 Get It

Tobacco use is predicted to result in over 1 billion deaths worldwide by the end of the 21 st century. How genetic variation contributes to the observed differential predisposition in the human population to drug dependence is unknown. The zebrafish ( Danio rerio ) is an emerging vertebrate model system for understanding the genetics of behavior. We developed a nicotine behavioral assay in zebrafish and applied it in a forward genetic screen using gene-breaking transposon mutagenesis. We used this method to molecularly characterize bdav /cct8 and hbog /gabbr1.2 as mutations with altered nicotine response. Each have a single human ortholog, identifying two points for potential scientific, diagnostic, and drug development for nicotine biology and cessation therapeutics. We show this insertional method generates mutant alleles that are reversible through Cre-mediated recombination, representing a conditional mutation system for the zebrafish. The combination of this reporter-tagged insertional mutagen approach and zebrafish provides a powerful platform for a rich array of questions amenable to genetic-based scientific inquiry, including the basis of behavior, epigenetics, plasticity, stress, memory, and learning.